Myeloma Paper of the Day, September 13th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: ALGONQUIN trial subgroup analysis of belantamab/pom/dex in triple class exposed/refractory myeloma finds ORR 86.4% in TCE vs 84.9% in TCR patients, ≥VGPR of 64% vs 68%, median PFS 18.3 vs 19.6 mos, and OS NR vs 34.4 mos.”

Source: Robert Orlowski/X

Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial

Authors: Arleigh McCurdy, Donna Reece, Martha L. Louzada, Darrell White, Stephen Parkin, Michael P. Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul and Suzanne Trudel.

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.